• National Institutes of Health, Postdoctoral Fellow, Laboratory of Dr. Bernard Moss, Laboratory of Viral Diseases, Bethesda, MD; 2004-2007
  • The University of Edinburgh, United Kingdom, Ph.D., Laboratory of Clinical and Molecular Virology Center for Infectious Diseases
  • The University of Edinburgh, United Kingdom, B.S., Department of Medical Microbiology, Faculty of Medicine
  • George Washington University Law School, J.D.

Bar Admissions

  • Maryland
  • District of Columbia
  • U.S. Patent and Trademark Office
Who We Are

Alan Craig Townsley, Ph.D.

T: 202.857.2278
F: 202.293.7860
Dr. Alan Craig Townsley is a partner at Sughrue Mion, and prior to entering the field of patent law, Dr. Townsley was a post-doctoral research fellow at the National Institutes of Health, Bethesda, MD, within the laboratory of Dr. Bernard Moss in the National Institute of Allergy and Infectious Diseases (NIAID), where Dr. Townsley’s post-doctoral research focused on poxvirus cell-entry mechanisms. He received his undergraduate degree in medical microbiology from The University of Edinburgh, United Kingdom, and his Ph.D. degree in molecular virology and immunology from The University of Edinburgh, for the study of gamma-herpesvirus-mediated immunoregulation. ‎With almost 10 years of experience in the laboratory setting before entering the field of patent law, ‎including research in genetics, virology, immunology and cell biology, ‎Dr. Townsley applies his considerable technical experience to the procurement of patents, both ‎foreign and domestic, and to assist in client counseling and patent portfolio management. Additionally, Dr. Townsley’s practice involves substantial due diligence and opinion work, including the drafting of patentability, freedom-to-operate, and invalidity opinions; and Inter Partes Review (IPR) matters.

Dr. Townsley’s practice focuses chiefly on complex biotechnology issues arising in the fields of genetics, molecular biology, and immunology. In particular, Dr. Townsley has considerable prosecution experience, and experience in preparing patentability-, freedom-to-operate-, and invalidity opinions, in areas such as therapeutic proteins, regulation of gene expression, genetically-modified organisms, and biological assays. More specifically, Dr. Townsley’s experience in this respect has involved technologies such as therapeutic antibodies, post-translational modifications, siRNAs and microRNAs, and transgenic animals.